Gold prices hit 2-week high as Trump-Fed feud escalates with Cook firing
Kevin Feeley, the Chief Financial Officer of GeneDx Holdings Corp. (NASDAQ:WGS), recently sold shares valued at approximately $87,334. The transaction, dated March 10, 2025, involved the sale of 922 shares of Class A Common Stock at a weighted average price of $94.72 per share. The sale comes amid significant market interest in GeneDx, which has delivered an impressive 839% return over the past year and currently maintains a "GOOD" Financial Health score according to InvestingPro analysis. This sale was conducted to cover tax obligations related to the vesting and settlement of restricted stock units (RSUs).
On March 9, 2025, Feeley acquired 2,462 shares of Class A Common Stock through the vesting of RSUs, which were settled for no monetary consideration. Following these transactions, Feeley holds 5,446 shares directly. The shares were sold in multiple transactions, with prices ranging from $90.50 to $94.85 per share.
In other recent news, GeneDx Holdings Corp reported exceptional financial results for the fourth quarter of 2024, surpassing both earnings and revenue projections. The company’s earnings per share reached $0.08, contrasting with the anticipated loss of $0.48, while revenue soared to $95.3 million, exceeding the expected $61.7 million. This marks GeneDx’s second consecutive profitable quarter, with a notable 101% year-over-year growth in exome and genome testing revenues. The company has also introduced a new Ultra Rapid Whole Genome Sequencing product, enhancing its service offerings.
GeneDx’s strategic efforts include expanding its sales team and implementing new operational strategies, contributing to its robust performance. The company has projected revenue guidance for 2025 between $350 million and $360 million, with expected growth of at least 30% in exome and genome volume. In terms of market analysis, GeneDx’s stock was recently upgraded by analysts at TD Cowen, reflecting positive sentiment around the company’s financial health and strategic direction. Additionally, GeneDx is exploring new opportunities in the adult market for neurodegenerative and cardiac conditions, aiming to broaden its market reach.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.